Nine Pharma Companies Ink Deals to Lower Drug Prices
Here’s a breakdown of the key information from the provided text regarding Trump’s drug pricing deals:
Core of the Deals:
* Price Reductions: Nine major pharmaceutical companies have agreed to lower drug prices for Americans.
* “Most Favored Nation” Pricing: They will sell existing drugs to Medicaid patients at the lowest prices offered in other countries (“most favored nation” prices) and guarantee similar pricing for new medicines.
* TrumpRx Website: The companies will list popular drugs on Trump’s upcoming direct-to-consumer website, TrumpRx, launching in january.
* U.S. Manufacturing investment: The deals are linked to companies investing further in U.S. manufacturing,possibly shielding them from Trump’s planned pharmaceutical tariffs.
Specific Company Pledges (Examples):
* Bristol Myers Squibb: Will offer its blockbuster blood thinner, Eliquis, for free to Medicaid patients.
* Gilead: Will offer its hepatitis C treatment, Epclusa, at a discounted price through a new program.
* Sanofi: Will offer discounts of nearly 70% on certain medicines through TrumpRx and other platforms.
* Merck: Will offer three diabetes medications (Januvia, Janumet, Janumet XR) at a roughly 70% discount to cash-paying patients, and extend this to a potential new cholesterol pill if approved.
Companies Not Yet Onboard (as of the article):
* Johnson & Johnson (expected to join soon)
* AbbVie
* Regeneron
Trump’s Claims:
* He calls this “the greatest victory for patient affordability in the history of American health care.”
* He states 14 out of 17 major pharmaceutical companies have agreed to lower prices.
Uncertainties:
* The full terms of the deals haven’t been released, so the breadth of their impact is unclear.
the article highlights Trump’s “most favored nation” policy, which aims to end what he calls “global freeloading” by increasing drug prices outside the U.S. and lowering them within the country.